Combined positron emission tomography/computed tomography (PET/CT) for imaging of orbital tumours and tumours extending into the orbit

Annemarie Klingenstein,1 Gerd-Ulrich Mueller-Lisse,2 Alexander R Haug,3,4 Aylin Garip-Kuebler,1 Christina V Miller,1 Christoph R Hintschich1

ABSTRACT
Objective To assess clinical and radiological performance of combined positron emission tomography/computed tomography (PET/CT) in patients with secondary and primary intraorbital tumours.

Methods 14 adults with secondary and 1 child with primary orbital masses underwent combined whole-body PET/CT. Radiopharmaceutical tracers applied were (18F)-fluorodeoxyglucose, (18F)-fluoroothylcholine (FEC) and (68Ga)-DOTATATE. Histopathology and/or all conventional radiographic work-up and clinical course served as standard of reference. Descriptive statistics and Fisher’s exact test were used for analysis.

Results PET/CT detected all orbital masses. All 15 patients had malignant disease. Local osseous infiltration was correctly identified in 11 patients. Lymph node metastases were present in two of eight patients (25%) with haematogenous orbital metastases and in five of six patients (83%) with infiltrative carcinoma (p=0.05). Further distant metastases were present in all eight patients suffering from orbital metastases, but only one patient with infiltrative carcinoma (17%) presented with disseminated disease (p=0.003). In one metastasis, PET/CT excluded vital orbital tumour tissue after radiation therapy. Local recurrence was detected in another patient suffering from prostate cancer.

Conclusion PET/CT is a sensitive tool for the detection and localisation of orbital masses, enabling assessment of both morphology and cell metabolism. Detailed imaging of the head and neck region with a small field-of-view should be performed when suspecting lymphatic metastases. As metastatic disease to the orbit is associated with advanced disease, focus should be laid on whole-body imaging for staging of these patients. Different radiopharmaceutical tracers can be applied to distinguish the origin of orbital metastases.

INTRODUCTION
Incidence and conventional imaging of orbital tumours
Orbital tumours account for approximately 0.1% of all tumours and 18% of all orbital diseases.1 Contrast-enhanced CT and MRI can be considered as the standard imaging techniques to evaluate orbital tumours.2 Positron emission tomography (PET) with (18F)-fluorodeoxyglucose (FDG) is a well-established tool for staging and restaging of patients with cancer of the mouth, pharynx and larynx3 and can be applied for detecting residual tumour or recurrence and for the identification of lymph node involvement.4 Orbital metastases are rare in clinical practice5 and usually occur in disseminated disease.6 Nearly all solid malignancies have been reported to metastasise to the orbit, but the most frequent primary tumours in adults spreading to the orbit are breast cancer (42%), lung cancer (11%), cancer of unknown primary (11%), prostate cancer (8.3%), cutaneous melanoma (5.2%), cancer of the gastrointestinal tract (4.4%) and kidney cancer (3.2%).7

Combined PET/CT imaging
In the past years, combined PET/CT imaging has emerged as a diagnostic modality and its importance has been proven in diagnosing and monitoring patients with different malignancies (eg, lymphoma, gastrointestinal tumours, non-small-cell lung cancer, cutaneous melanoma, breast cancer).8–10 PET/CT successfully combines data on metabolic activity obtained by PET with detailed morphological information gained from CT. Combined application helps to minimise the limitations of each modality by itself.7,11

Beyond (18F)-FDG, different other radiopharmaceutical tracers are available for PET/CT. (68Ga)-DOTATATE (68-Ga-1,4,7,10-tetraazacyclododecane-N,N’N’’N’’-tetraacetic acid-d-Phe(1), Tyr(3)-octreotate), a selective somatostatin receptor (SSTR) agonist,12 is applied for the detection of meningioma or neuroendocrine tumours. For imaging of other tumour entities that might metastasise to the orbit, specific radiopharmaceutical tracers such as, for example, (18F)-fluoroothylcholine ((18F)-FEC) or (68Ga)-PSMA (prostate-specific membrane antigen) in prostate cancer are applied regularly in clinical routine among others.13

PET/CT for the detection of orbital tumours
Since orbital tumours are rare disease entities, literature on the relevance of PET/CT for their detection to date is very limited. While PET/CT has already been considered as a new method for diagnosing, staging, and restaging patients with orbital lymphoma,14 the advantage in solid orbital tumours is regarded controversial.15 Our study group has reported on (68Ga)-DOTA-TATE PET/CT as a useful tool in imaging orbital meningiomas previously.12 The objective of the current study was to evaluate the performance of the combined PET/CT scanner in patients with primary and secondary solid orbital tumours.

MATERIAL AND METHODS
Patient selection
Selected patients were included retrospectively from our PET/CT database. We searched our PET/CT
PET/CT acquisition and image analysis

PET/CT scanning was performed employing either a Philips Gemini System (Philips Medical Systems, Hamburg, Germany) or a Siemens Biograph TruePoint 64 (Siemens Medical Solutions, Erlangen, Germany) or a GE Discovery 690 (GE Healthcare, Munich, Germany). After fasting for 6 h, 20 mg butylscopolamine (Buscopan; Boehringer Ingelheim, Ingelheim, Germany), 20 mg furosemide and 250 MBq (range 217–376 MBq) of the radiopharmaceutical tracer were applied intravenously in adults ((18F)-FDG in 11, (68Ga)-DOTATATE in 1 and (18F)-FEC in 2 patients). In the child 110 MBq of (18F)-FDG was administered. The imaging protocol included a low-dose CT scan for attenuation correction of PET imaging data acquired 60 min after intravenous administration of the PET tracer, a whole-body PET scan obtained with multiple bed positions, typically ranging from the top of the head to the upper third of the thigh and a diagnostic contrast-enhanced multidetector-row CT scan covering the range of the previous PET scan. Using the Philips Gemini PET/CT, low-dose CT scan settings were 20 mA, 140 kV and 512×512 matrix; PET data were acquired with a field-of-view of 10 cm and 3 min per bed position and the diagnostic CT scan was performed with 100–190 mA, depending on the scanned region, 120 kV collimation 2×5 mm and pitch 1.5, in the venous phase, 75 s after intravenous injection of iodine-containing contrast agent (Ultravist 300; Schering, Berlin, Germany) at a rate of 2.5 mL/s. Similar protocols were applied with the other PET/CT scanners.

In one patient, due to known renal insufficiency, no contrast agent was employed. Also in the child, CT was performed without intravenous contrast agent. The reconstruction of the PET data was performed in three dimensional mode, with and without attenuation correction. CT data were evaluated alone, after multiplanar reformatting (axial, coronal, sagittal), and as combined PET/CT images as generated in with the Hermes system (Hermes Medical Solutions, London, UK). Evaluation of malignancy on CT was based on tumour morphology and patterns of contrast enhancement. For lymph nodes, CT criteria of malignancy included an axial diameter exceeding 10 mm and/or nodal clustering (three or more lymph nodes adjacent to each other), central necrosis and/or contrast enhancement. PET images were evaluated for regions of focally increased glucose uptake, typically with SUVmax exceeding a level of 5.

Validation of PET/CT findings

Histology served as standard of reference in 10 patients. The remaining five patients had proven distant metastases from their underlying disease making orbital metastasis most probable. Whenever histopathology was not available, all previous and subsequent imaging studies (MRI, PET/CT) along with the clinical course and monitored treatment response served as standard of reference (for details, please see Table 1).

Statistical analysis

Statistical analysis was performed using SPSS (V23.0) for Windows (IBM; Armonk, New York, USA) employing Fisher’s exact test and Microsoft Excel for Mac 2011.

RESULTS

Demographic data

Fifteen patients with orbital masses underwent whole-body PET/CT scanning.

Adult patients’ median age was 70 years (range 46–79 years). We also included one boy aged 7 years at the time of PET/CT examination. Six patients had an orbital mass on the right eye, eight patients on the left eye and one patient presented with bilateral orbital infiltration. Eight patients were male and seven were female.

All orbital masses were detected by whole-body PET/CT (for patient details, see Table 1). Osseous infiltration was noted in 11 orbital tumours (five metastases, five infiltrative carcinomas and one rhabdomyosarcoma).

PET/CT in rhabdomyosarcoma (n=1)

Patient number 9 suffered from histology-proven rhabdomyosarcoma which infiltrated the roof and the apex of the orbit. Clinical ophthalmological examination revealed papilloedema and exophthalmos. PET/CT correctly ruled out systemic metastasis.

PET/CT in secondary orbital tumours (n=14)

Whole-body PET/CT correctly assessed six patients with continuous tumour spread to the orbit and eight orbital metastases. Histology-proven primary tumours of these patients included breast cancer (n=3), prostate cancer (n=2), invasive follicular thyroid carcinoma (n=1), cutaneous melanoma (n=1) and neuroendocrine carcinoma of the small intestine (n=1). While (18F)-FDG accumulation indicates an elevated glucose metabolism in general, (18F)-FEC and (68Ga)-DOTATATE were specifically employed for suspected metastasis of prostate cancer and neuroendocrine carcinoma, respectively. Further metastatic sites in patients with orbital metastases included osseous (n=8), hepatic (n=4), pulmonary (n=2) as well as one cutaneous, muscular and endometrium metastasis, respectively.

Lymph node metastases were present in two of eight patients with haematogenous tumour spread (25%) and in five of six patients with continuous tumour spread (83%). Lymph node involvement was more frequent in patients with local carcinomas extending into the orbit (Fisher’s exact test, p=0.05). Further organ involvement was present in all eight patients suffering from orbital metastases, whereas only one patient with infiltrative carcinoma had further distant metastases (17%). This was highly significant (Fisher’s exact test, p=0.003). These results are summarised in Table 2.

In metastatic patients, seven orbital metastases expressed an elevated metabolism indicating vital tumour tissue and consequently leading to treatment decision. In one patient, PET/CT could exclude vital orbital tumour tissue after radiation therapy (patient number 13, Figure 2), yet further distant lymph node, pulmonary as well as osseous metastases were present. The patient then underwent chemotherapy.
In patient 1 suffering from prostate cancer, previously unknown local recurrence was detected by (18F)-FEC PET/CT (figure 3). Thus, PET/CT had influence on treatment decision in all patients.

DISCUSSION
Combined morphological and metabolic data in PET/CT improve diagnostic accuracy. This plays an important role in the selection of adequate therapy. Higher patient convenience, saving of time and greater diagnostic confidence are important advantages of combined imaging.16

PET/CT in the child presenting with an orbital mass
In spite of the radiation exposure, PET/CT with reduced dose (110 MBq) was applied in one case of a primary orbital tumour. The child was symptomatic and presented with apparent exophthalmos and papilloedema implied neoplastic growth. For paediatric rhabdomyosarcoma, PET/CT has already been proven superior to conventional radiological evaluation in the detection of distant metastases17 and lymph node metastases18 and was superior in detecting objective response after chemotherapy compared with conventional imaging methods (92% vs 84%).18 Whole-body (18F)-FDG PET/CT may be useful in detecting metastases of rhabdomyosarcoma that are not clinically evident and upstaging in comparison with MRI staging (lymph node and osseous metastases) has been reported previously.19 PET/CT has thus been proven a meaningful tool in the staging of carcinoma and rhabdomyosarcoma.20 In the child with rhabdomyosarcoma in this study, PET/CT was successfully employed for staging (exclusion of further distant metastasis) and restaging after chemotherapy.

Table 1 Overview of patients (n=15) with primary and secondary orbital masses who underwent combined PET/CT

<table>
<thead>
<tr>
<th>Pt. ID (n=15)</th>
<th>Gender</th>
<th>Age at PET/CT (y)</th>
<th>Therapy</th>
<th>Eye within the orbit</th>
<th>Tumour localisation</th>
<th>Final diagnosis</th>
<th>PET-Tracer</th>
<th>Validation</th>
<th>Ocular symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>M</td>
<td>68</td>
<td>CyberKnife</td>
<td>OS</td>
<td>Superiorly</td>
<td>Metastasis (prostate cancer)</td>
<td>(18F)-FEC</td>
<td>MRI</td>
<td>BCVA ↓</td>
</tr>
<tr>
<td>2</td>
<td>M</td>
<td>71</td>
<td>CyberKnife, hormone therapy</td>
<td>OD</td>
<td>Temporally</td>
<td>Metastasis (prostate cancer)</td>
<td>(18F)-FEC</td>
<td>MRI</td>
<td>None</td>
</tr>
<tr>
<td>3</td>
<td>F</td>
<td>62</td>
<td>CyberKnife, chemotherapy</td>
<td>OS</td>
<td>Inferiorly</td>
<td>Metastasis (breast cancer)</td>
<td>(18F)-FDG</td>
<td>MRI, PET/CT</td>
<td>None</td>
</tr>
<tr>
<td>4</td>
<td>F</td>
<td>46</td>
<td>Surgical resection, radiation therapy</td>
<td>OD</td>
<td>Medially</td>
<td>Neuroendocrine carcinoma</td>
<td>(18F)-FDG</td>
<td>Histopathology</td>
<td>VF defects</td>
</tr>
<tr>
<td>5</td>
<td>F</td>
<td>60</td>
<td>Surgical resection, radiation therapy</td>
<td>OS</td>
<td>Superiorly</td>
<td>Metastasis (thyroid cancer)</td>
<td>(18F)-FDG</td>
<td>Histopathology</td>
<td>Double vision</td>
</tr>
<tr>
<td>6</td>
<td>M</td>
<td>72</td>
<td>Radiation therapy, DOTA therapy</td>
<td>OS</td>
<td>Temporally</td>
<td>Metastasis (neuroendocrine carcinoma)</td>
<td>(68Ga)-DOTATATE</td>
<td>MRI</td>
<td>None</td>
</tr>
<tr>
<td>7</td>
<td>F</td>
<td>58</td>
<td>Radiation therapy, hormone therapy</td>
<td>OD</td>
<td>Medially</td>
<td>Metastasis (breast cancer)</td>
<td>(18F)-FDG</td>
<td>MRI</td>
<td>Enophthalmos</td>
</tr>
<tr>
<td>8</td>
<td>M</td>
<td>71</td>
<td>Surgical resection</td>
<td>OD</td>
<td>Medially</td>
<td>Squamous cell carcinoma</td>
<td>(18F)-FDG</td>
<td>Histopathology</td>
<td>Skin alteration</td>
</tr>
<tr>
<td>9</td>
<td>M</td>
<td>7</td>
<td>Chemotherapy</td>
<td>OS</td>
<td>Superiorly, orbital apex</td>
<td>Rhabdomyosarcoma</td>
<td>(18F)-FDG</td>
<td>Histopathology</td>
<td>Exophthalmos</td>
</tr>
<tr>
<td>10</td>
<td>M</td>
<td>70</td>
<td>Radiation therapy</td>
<td>OD</td>
<td>Medially</td>
<td>Nasopharyngeal carcinoma</td>
<td>(18F)-FDG</td>
<td>Histopathology</td>
<td>BCVA ↓</td>
</tr>
<tr>
<td>11</td>
<td>F</td>
<td>79</td>
<td>Surgical resection</td>
<td>OS</td>
<td>Superiorly, mediadly</td>
<td>Meibomian gland carcinoma</td>
<td>(18F)-FDG</td>
<td>Histopathology</td>
<td>Inflammation</td>
</tr>
<tr>
<td>12</td>
<td>M</td>
<td>76</td>
<td>Surgical resection</td>
<td>OD</td>
<td>Medially, lacrimal duct</td>
<td>Squamous cell carcinoma</td>
<td>(18F)-FDG</td>
<td>Histopathology</td>
<td>Skin alteration</td>
</tr>
<tr>
<td>13</td>
<td>F</td>
<td>76</td>
<td>Chemotherapy, Radiotherapy</td>
<td>OS</td>
<td>Superiorly</td>
<td>Metastasis (breast cancer)</td>
<td>(18F)-FDG</td>
<td>Histopathology</td>
<td>Ptosis</td>
</tr>
<tr>
<td>14</td>
<td>M</td>
<td>68</td>
<td>Chemotherapy</td>
<td>OD</td>
<td>Medially</td>
<td>Neuroendocrine carcinoma</td>
<td>(18F)-FDG</td>
<td>Histopathology</td>
<td>Double vision</td>
</tr>
<tr>
<td>15</td>
<td>F</td>
<td>76</td>
<td>Radiation therapy, immunotherapy</td>
<td>OS</td>
<td>Orbital apex</td>
<td>Metastasis (cutaneous melanoma)</td>
<td>(18F)-FDG</td>
<td>Histopathology</td>
<td>BCVA ↓</td>
</tr>
</tbody>
</table>

BCVA ↓ Decrease in best-corrected visual acuity; FDG, fluorodeoxyglucose; FEC, fluoroethylcholine; OD, Right eye; OS, Left eye; PET, positron emission tomography; Pt., patient; VF, Visual field.
PET/CT for detection of lymph node metastases in orbital tumours

We employed PET/CT for diagnosing metastasis to the orbit and for detecting the extent of lymph node involvement from invasive malignancies. This has been widely evaluated for the head and neck region in cervical carcinoma of unknown primary. PET/CT has the potential to improve the management of patients with carcinoma in the sinus/nasal area and orbit. Variable diagnostic accuracy has been shown for (18F)-FDG PET in the detection of different histological tumour entities.

Lymph node staging has extensive consequences for the patients ranging from no adjuvant therapy to very radical therapy like neck dissection, brachytherapy or chemotherapy in advanced tumours. Advantages of lymph node evaluation via PET/CT versus sentinel lymph node biopsy are of interest for the tumours included in our study that extended into the orbit. PET/CT is less invasive than biopsy enabling whole-body evaluation within the same examination. Furthermore, indication for sentinel lymph node biopsy in conjunctival and eyelid tumours is limited to specific tumour stages, according to a recent review, and multi-institutional controlled trials are warranted. Data on sentinel lymph node biopsy on tumours extending into the orbit are even more limited. A comparative study on the sensitivity and specificity of sentinel lymph node biopsy and lymph node staging via PET/CT would be of great value. Additional lymph node metastases may modify treatment decision (neck dissection or delineation of the radiation treatment field).

Field-of-view in PET/CT

In clinical practice in both nuclear medicine and radiology, increasing spatial resolution of images is achieved by decreasing the field-of-view, because the whole reconstruction matrix is used for a smaller anatomical region. Consequently, this reduces pixel size within the images. The field-of-view reflects the maximum diameter of the reconstructed digital image. Its value can be selected by the radiologist depending on the dimensions of the anatomical region of interest. The choice of a small field-of-view allows increased spatial resolution within the image, because the whole reconstruction matrix is used for a smaller region. A large field-of-view is usually selected for whole-body-PET/CT imaging to fully include even the widest axial dimensions of the human body, that is, the shoulders and the hips, in search of distant metastasis. In this study, as orbital metastases were associated with further distant metastases in all cases, a large field-of-view in PET/CT was reasonable in order not to overlook any distant metastasis. However, detailed imaging of the head and neck region was of utmost importance in lesions extending into the orbit. These infiltrative tumours were more likely to develop lymph node metastases rather than distant metastases. Therefore, additional image reconstructions with a small field-of-view were chosen to cover the head and neck regions in these patients with high spatial resolution. Whenever imaging raw data are kept available, the field-of-view can be changed in retrospect.

PET/CT in orbital metastases

The actual incidence of metastases to the eye and orbit is difficult to quantify, as patients may remain asymptomatic and succumb to their primary cancer before clinical detection of the ocular metastasis. Yet, with improvements in systemic therapy and oncological management, patients suffering from metastatic cancer survive longer and, therefore, orbital metastases may manifest more frequently.

Of course, clinical examination remains the first important method for evaluation of orbital symptoms. However, for biopsy planning, CT is necessary for assessment of bony invasion or if the tumour is localised in the orbital apex, making ultrasound examination difficult.

Whole-body PET/CT imaging can be employed for detecting primary site in metastatic disease and defining the total extent of disseminated disease. PET/CT can indicate vital tumour metabolism, and selectively binding radiopharmaceutical tracers, which were applied for diagnostics of prostate cancer or neuroendocrine tumour metastases in this study, can determine the origin of tumour cells. PET may overcome CT limitations by its ability to visualise vital tumour tissue by increased FDG uptake and therefore identify residual cancer or recurrence. In this study, recurrence of prostate cancer was detected on (18F)-FEC PET/CT in one patient, thus modifying treatment. In a large retrospective study evaluating different non-typical sites of metastasis of neuroendocrine tumours, the most common locations were cardiac and breast metastases followed by retro-orbital metastases. In cases with known neuroendocrine tumours, (68Ga)-DOTATATE PET/CT can delineate the orbital mass in question and can determine tumour biology in terms of SSRT expression. In the present study, a previously unknown orbital metastasis could be diagnosed correctly as such with (68Ga)-DOTATATE PET/CT.

In PET/CT, detection of distant metastases may be performed within the same whole-body scan. This has been reported in

<table>
<thead>
<tr>
<th>Table 2</th>
<th>Tumour spread in adults with orbital metastases vs tumours extending into the orbit</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Orbital metastases</td>
</tr>
<tr>
<td>Bony infiltration</td>
<td>(n=8) 5 (62%)</td>
</tr>
<tr>
<td>Lymph node metastases</td>
<td>2 (25%)</td>
</tr>
<tr>
<td>Further distant metastases</td>
<td>8 (100%)</td>
</tr>
</tbody>
</table>

n.s., not significant.

Figure 2 Intraorbital breast cancer metastasis invading the levator complex demonstrating low fluorodeoxyglucose uptake after radiation therapy (patient 13). The CT scan on the left shows the orbital metastasis before (within the red frame) and after radiotherapy. The scan on the right is taken from the same examination after therapy but is showing combined positron emission tomography/CT imaging.
Figure 3  Temporal orbital metastasis as shown on CT and positron emission tomography (PET) (above, patient 1). The CT scan on the left is showing bony infiltration by the orbital mass. The PET scan on the right is demonstrating obviously elevated tracer uptake of the lesion in question. The CT scan on the left (below) is showing a previously unknown local recurrence of prostate cancer and the (18F)-fluorothymidine PET image on the right demonstrates its elevated tumour metabolism.

27% of patients by Wild et al² for carcinomas of the sinus/nasal area and orbit.² The group reported superior performance of PET/CT for restaging locoregional carcinoma of the sinus, nasal area and orbit, but not for initial staging.

We found additional systemic metastases present in eight patients who presented with orbital metastases (100%) within this study. Orbital metastases usually spread hematogenously.⁶ Disseminated disease was significantly more frequent in patients with haematogenous orbital metastases than in patients with infiltrative tumour growth (p=0.003). We therefore conclude that whole-body PET/CT including imaging of the head and orbit should be employed in patients with systemic metastases presenting with recent orbital symptoms. Additionally, PET/CT should be performed in patients with tumour history without known metastasis and orbital symptoms as these symptoms can be the first manifestation of diffuse systemic metastases. PET/CT seems most appropriate for advanced cancers of the orbit, eyelid and eye with high risk of distant metastasis.¹³

CONCLUSION
By employing PET/CT, both tumour morphology and cell metabolism can be assessed in one single examination, thereby helping in overcoming the limitations of each modality used separately. As orbital metastases did not present as solitary findings in the present study, whole-body staging is of great value for the evaluation of metastatic spread and specific radiopharmaceutical tracers can be employed for this purpose. For infiltrating tumours associated with lymph node metastases, PET/CT has proven valuable for the evaluation of lymph node involvement. Additionally, PET/CT can be of importance in particular settings of paediatric ocular diagnostics.

Correction notice  This article has been corrected since it was published Online First. The first two column headings in table 1 have been corrected from Pt. ID (n=16) and Gender (m:f=8:8) to Pt. ID (n=15) and Gender (m:f=8:7), respectively.

Contributors  All authors (AK, G-UM-L, ARH, AG-K, CVM and CRH) made substantial contributions to the conception and design of the manuscript and the acquisition, analysis and interpretation of data for the work and drafting the work and critical revision for important intellectual content. They have approved the final version to be published and have agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Competing interests  None declared.

Ethics approval  Institutional review board of Ophthalmology.

Provenance and peer review  Not commissioned; externally peer reviewed.

REFERENCES


